1. FIGURE 2. Graph showing percentage of lesions with residual hemostatic agent. *, P < for negative control and Arista (Medafor, Inc., Minneapolis, MN) versus Avitene (Alcon, Inc., Humacao, PR), Flo Seal (Baxter Healthcare Corp., Deerfield, IL), and Surgicel (Ethicon, Inc., Somerville, NJ), and positive control on Days 3 and 7. †, P < 0.05 for negative control and Arista versus Avitene, FloSeal, and Surgicel on Day 14. ‡, P < 0.05 for negative control and Arista versus FloSeal and positive control on Day 28.
From: Comparative Safety and Efficacy of Topical Hemostatic Agents in a Rat Neurosurgical Model
Oper Neurosurg (Hagerstown). 2008;63(suppl_4):ONS369-ONS372. doi: /01.NEU DD
Oper Neurosurg (Hagerstown) | © 2008 by the Congress of Neurological Surgeons 1